Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)

Bruton’s tyrosine kinase (BTK), expressed in B cells and cells of innate immunity, including microglia, is an essential signaling element downstream of the B‐cell receptor and Fc‐receptors. Tolebrutinib (PRN2246, SAR442168) is a potent BTK inhibitor that covalently binds the kinase, resulting in dur...

Descripción completa

Detalles Bibliográficos
Autores principales: Owens, Timothy D., Smith, Patrick F., Redfern, Andrew, Xing, Yan, Shu, Jin, Karr, Dane E., Hartmann, Sonja, Francesco, Michelle R., Langrish, Claire L., Nunn, Philip A., Gourlay, Steven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841436/
https://www.ncbi.nlm.nih.gov/pubmed/34724345
http://dx.doi.org/10.1111/cts.13162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841436/
https://www.ncbi.nlm.nih.gov/pubmed/34724345
http://dx.doi.org/10.1111/cts.13162

Ejemplares similares